Cover Image
市場調查報告書

α-突觸核蛋白:開發中產品分析

Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365788
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
α-突觸核蛋白:開發中產品分析 Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 84 Pages
簡介

本報告提供以α-突觸核蛋白為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

α-突觸核蛋白 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • AC Immune SA
  • AFFiRiS AG
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • NeuroPhage Pharmaceuticals, Inc.
  • Neuropore Therapies, Inc.
  • nLife Therapeutics, S.L.
  • Primary Peptides, Inc.
  • Prothena Corporation Plc
  • QR Pharma, Inc.
  • reMYND NV
  • Synovo GmbH

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0262TDB

Summary

Global Markets Direct's, 'Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016', provides in depth analysis on Alpha-Synuclein (alphaSyn or SNCA) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Alpha-Synuclein (alphaSyn or SNCA)
  • The report reviews Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Alpha-Synuclein (alphaSyn or SNCA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alpha-Synuclein (alphaSyn or SNCA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alpha-Synuclein (alphaSyn or SNCA) Overview
  • Therapeutics Development
    • Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Stage of Development
    • Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Therapy Area
    • Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Indication
  • Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Companies
  • Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Universities/Institutes
  • Alpha-Synuclein (alphaSyn or SNCA) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Alpha-Synuclein (alphaSyn or SNCA) - Companies Involved in Therapeutics Development
    • AC Immune SA
    • AFFiRiS AG
    • BioArctic Neuroscience AB
    • Biogen, Inc.
    • NeuroPhage Pharmaceuticals, Inc.
    • Neuropore Therapies, Inc.
    • nLife Therapeutics, S.L.
    • Primary Peptides, Inc.
    • Prothena Corporation Plc
    • QR Pharma, Inc.
    • reMYND NV
    • Synovo GmbH
  • Alpha-Synuclein (alphaSyn or SNCA) - Drug Profiles
    • BAN-0805 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIIB-054 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLR-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPC-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kenterin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLFPD-1233 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-088 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-20011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPT-3G - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PD-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Posiphen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRX-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • quinpramine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReS-12S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ReS-9S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trehalose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target Alpha-Synuclein for Parkinson's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alpha-Synuclein (alphaSyn or SNCA) - Dormant Projects
  • Alpha-Synuclein (alphaSyn or SNCA) - Featured News & Press Releases
    • Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11
    • Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials
    • Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference
    • Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer's Association International Conference
    • Jul 02, 2015: BIIB054 reached significant milestone
    • Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease
    • Jun 15, 2015: BioArctic Neuroscience Parkinson's disease program receives grant from VINNOVA
    • Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders
    • Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinson's disease
    • Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease
    • Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimer's & Parkinson's Diseases
    • Dec 09, 2014: Parkinson's Vaccine: EU-Team Launches Clinical Trial Vaccine candidate based on proprietary technology by AFFiRiS
    • Nov 14, 2014: NeuroPhage's GAIM Technology Chosen As Top Project To Watch For The Therapeutic Area Partnerships Conference
    • Aug 26, 2014: Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress
    • Jul 31, 2014: First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by AC Immune SA, H1 2016
  • Pipeline by AFFiRiS AG, H1 2016
  • Pipeline by BioArctic Neuroscience AB, H1 2016
  • Pipeline by Biogen, Inc., H1 2016
  • Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016
  • Pipeline by Neuropore Therapies, Inc., H1 2016
  • Pipeline by nLife Therapeutics, S.L., H1 2016
  • Pipeline by Primary Peptides, Inc., H1 2016
  • Pipeline by Prothena Corporation Plc, H1 2016
  • Pipeline by QR Pharma, Inc., H1 2016
  • Pipeline by reMYND NV, H1 2016
  • Pipeline by Synovo GmbH, H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top